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Abstract
Background: The golden retriever muscular dystrophy (GRMD) dogs represent the best available
animal model for therapeutic trials aiming at the future treatment of human Duchenne muscular
dystrophy (DMD). We have obtained a rare litter of six GRMD dogs (3 males and 3 females) born
from an affected male and a carrier female which were submitted to a therapeutic trial with adult
human stem cells to investigate their capacity to engraft into dogs muscles by local as compared to
systemic injection without any immunosuppression.
Methods: Human Immature Dental Pulp Stem Cells (hIDPSC) were transplanted into 4 littermate
dogs aged 28 to 40 days by either arterial or muscular injections. Two non-injected dogs were kept
as controls. Clinical translation effects were analyzed since immune reactions by blood exams and
physical scores capacity of each dog. Samples from biopsies were checked by
immunohistochemistry (dystrophin markers) and FISH for human probes.
Results and Discussion: We analyzed the cells' ability in respect to migrate, engraftment, and
myogenic potential, and the expression of human dystrophin in affected muscles. Additionally, the
efficiency of single and consecutive early transplantation was compared. Chimeric muscle fibers
were detected by immunofluorescence and fluorescent in situ hybridisation (FISH) using human
antibodies and X and Y DNA probes. No signs of immune rejection were observed and these
results suggested that hIDPSC cell transplantation may be done without immunosuppression. We
showed that hIDPSC presented significant engraftment in GRMD dog muscles, although human
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dystrophin expression was modest and limited to several muscle fibers. Better clinical condition
was also observed in the dog, which received monthly arterial injections and is still clinically stable
at 25 months of age.
Conclusion: Our data suggested that systemic multiple deliveries seemed more effective than
local injections. These findings open important avenues for further researches.
Background
Duchenne Muscular Dystrophy (DMD) is a lethal X-
linked disorder that affects 1 in 3,500 newborn human
males. It is caused by mutations in a large gene located at
Xp21 that encodes the muscle protein dystrophin [1]. One
third of DMD cases result from new mutations, whereas
the remaining are maternally inherited. Affected boys are
confined to a wheelchair around age 10 to 12 and later
develop respiratory and cardiac problems that lead to
death usually in the third or fourth decade.
Satellite cells are spare stem-cells responsible for muscle
growth and regeneration. Replacement of defective mus-
cle cells by the patient's satellite cells has been pursued for
a long time [2,3]. Other alternative sources of stem cells
(SC) such as bone marrow, cord-blood or adipose tissue
have been tested in the mdx mouse, which is the murine
model for human DMD. These experiments resulted in
the incorporation of donor-derived nuclei into muscle,
and the partial restoration of dystrophin expression in the
affected muscle [4]. However, the mdx mouse does not
present evident muscle weakness, with the exception of
significant histopathological alterations in the diaphragm
[5]. Myoblasts transplantation has also been tried for skel-
etal muscle tissue engineering [6] but it failed due to the
immunogenic properties of these cells. A new strategy to
overcome this obstacle has been recently developed
through myoblast transplantation tolerance with anti-
CD45RB, anti-CD154 and mixed chimerism [7].
The closest model for human DMD is the golden retriever
muscular dystrophy (GRMD) dog, which has a splice
acceptor site mutation in intron 6, causing a frameshift
due to deletion of exon 7 from the mature mRNA [8]. This
mutation results in the absence of the muscle protein dys-
trophin [9].
In the first reported trial using GRMD dogs, bone marrow
hematopoietic SC were transplanted from normal litter
mates to immunosuppressed GRMD dogs. Nevertheless,
dystrophin expression was not restored [10]. In another
study, it was suggested that mesoangioblast multipotent
cells from dorsal aorta improved muscle function when
transplanted into dystrophic dogs [11]. The latter authors
used both heterologous wild-type (WT) and autologous
genetically modified canine mesoangioblasts in their
experiments. In their study, the authors suggested that
mesoangioblasts are promising cells to be used in SC ther-
apy for DMD patients. However, because these studies
were performed under different regimes of immunosup-
pression, one cannot rule out that immunosuppression
alone may be responsible for clinical improvement as in
DMD boys, as it has been suggested in other studies [12].
We recently reported the successful isolation of a popula-
tion of hIDPSC from dental pulp of non-exfoliated decid-
uous teeth. Under standard culture conditions, these cells
express both the embryonic stem (ES) cells transcriptional
factors Oct4 and Nanog as well as surface markers of mes-
enchymal stem cells (MSC) such as CD105, CD73, and
CD13. Nevertheless, they lack the expression of CD45,
CD34, CD14, CD43, and of HLA-DR. These cells are able
to undergo spontaneous and induced in vitro differentia-
tion into osteoblasts, adipocytes and chondroblasts, mus-
cle cells, and into neurons in vitro. After transplantation
into normal mice, these cells show significant engraft-
ment in liver, spleen, brain and kidney, among others
[13].
Recently, hIDPSC, which are constituted by a homogene-
ous population positive for MSC markers, were shown to
contribute for the reconstruction of large cranial defects
produced in non immunosuppressed rats after their trans-
plantation onto collagen membrane, without presenting
any graft rejection [14]. Furthermore, populations of den-
tal pulp MSC (DP-MSC) similar to those of hIDPSC, with
immunosuppressive activity were described [15]. Analysis
of their proliferation activity demonstrated that it was sig-
nificantly higher in DP-MSC, when compared to those
from bone marrow. Similarly to bone marrow MSC, these
cells inhibited the proliferation of phytohemagglutinin
stimulated T-cells, presenting an even stronger effect than
in BM-MSC [15,16]. Other authors reported that DPSC
can survive and engraft in ischemic environments in non
immunosuppressed rats with acute myocardial infarction
[17]. Taken together these data led us to investigate the
myogenic potential of these cells in GRMD dogs.
Herein, we show results obtained after early transplanta-
tion of hIDPSC in four affected litter-mate GRMD dogs at
an early age (two males and two females) with no use of
immune suppression based on recent investigation. With
this study we aimed at analyzing the cells ability for
migration, engraftment, myogenic potential and expres-
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sion of human dystrophin in affected muscles. Addition-
ally, the efficiency of single and serial early
transplantation were compared with the subsequent eval-
uation of the dog's clinical condition without the interfer-
ence of immunosuppression protocols.
Materials and Methods
Dogs genotyping
Clinical studies were approved by the ethical committee
of the School of Veterinary Medicine and Animal Science
of São Paulo University. The animals were identified by
numbers and experimental procedures were described in
Table 1. DMD genotyping was done from blood genomic
DNA extracted with GFX Genomic Blood DNA Purifica-
tion Kit (GE Healthcare, Piscataway, NJ – USA/Canada)
and established as previously reported [18]. DMD diagno-
sis was confirmed by restriction digestion of PCR products
of the dystrophin gene with Sau96I and by elevated serum
creatine kinase (CK).
Mouse model
Normal mice were used to investigate the ability of
hIDPSC migration by intraperitoneal injections and
engraftment capacity of these cells without immunosup-
pression.
Cell culture
Cells were obtained and characterized as described previ-
ously [13]. Shortly, dental pulp was extracted from nor-
mal exfoliated human deciduous teeth of 5- to 7-year-old
children under local anesthetic. Tissue explant of dental
pulp was used to isolate the cells. Human IDPSC cultures
were maintained in DMEM/F12 (Dulbecco's-modified
Eagle's medium/Ham's F12, 1:1, Invitrogen, Carlsbad,
CA) supplemented with 15% fetal bovine serum (FBS,
Hyclone, Washington), 100 units/ml penicillin, 100
units/ml streptomycin, 2 mM L-glutamine, and 2 mM
nonessential amino acids. Cells were maintained semi-
confluent to prevent their differentiation and replaced
every 4 or 5 days. Medium was replaced daily. Human
IDPSC were incubated at 37°C in a high humidity envi-
ronment with 5% CO2.
FACS analysis
Monoclonal anti-human SH2 (CD105, Serotec, Oxford,
UK), SH3 and SH4 (CD73) (Case Western Reserve Uni-
versity, Cleveland, Ohio, USA) antibodies against cell sur-
face molecules and their respective isotype controls were
used in flow cytometry analysis. About 106 cells were incu-
bated with primary antibody for 30 minutes at 4°C and
washed in PBS with 2% FBS and 1 M sodium azide
(buffer) followed by addition of secondary anti-mouse-PE
– conjugated antibody according to manufacturer's
Table 1: GRMD dogs, born April, 2006 used for IDPSC transplantation and respective controls. 
Dog n° Dog name Cell Treatment Onset treatment Biopsy after 1a 
injection
Progression/
motility
Physical score Outcome of 
experiment at 
time ...
180d 365d
 Laka 2L5 Control - 0 d Severe/major 
decline
4 † Died (300d)
FC 107 d Ascite
 Lancy 2L6 hlDPSC – S Just with 107 d Severe/major 
decline
3 † Died (240d)
FT1-S 28 d Ascite
 Amandita 2L4 hlDPSC – IM Just with 107 d Mild/modest 
decline
4 † Died (480d)
FT2-IM 28 d Cardiac failure
 Bis 2L2 Control - 117 d Severe/major 
decline
2 17 Alive
MC
 Chokito 2L3 hlDPSC – S Start with 44 d 47 d Mild/modest 
decline
5 11 Alive and well
MT1-S
Followed by 8 
injections/month
117 d
365 d
 Toddy 2L7 hlDPSC – IM Start with 44 d 47 d Severe/major 
decline
6 † (24) Died (370d)
MT2-IM Followed by 5 
injections/month
117 d Gastric 
Malabsorption 
deficiency
All animals were descendant of the GRMD couple Peter (affected) × Lady (carrier)
Journal of Translational Medicine 2008, 6:35 http://www.translational-medicine.com/content/6/1/35
Page 4 of 13
(page number not for citation purposes)
instructions (Becton Dickinson, NJ, USA; Guava Technol-
ogies, CA). Negative controls were also performed incu-
bating the cells in PBS followed by incubation with
respective secondary antibody only. Results were analyzed
using Guava Express®Plus software (Guava Technologies,
Hayward, CA, USA). Flow cytometry was analyzed using a
fluorescence-activated cell sorter (FACS, Becton, Dickin-
son, San Jose, CA) with CELL Quest program (Becton,
Dickinson, San Jose, CA).
In vitro myogenic differentiation of hIDPSC
Cells were cultured in DMEM-HG medium supplemented
with 10% fetal bovine serum (FBS, Hyclone, Washing-
ton), 5% horse serum, 0.1 M dexamethasone, 50 nM
hydrocortisone (Sigma Aldrich, São Paulo, SP), 1% anti-
biotic (100 units/ml penicillin and 100 mg/ml streptomy-
cin; Invitrogen, São Paulo, SP) for 60 days.
Fluorescent dye staining of hIDPSC
The culture cell was washed twice in calcium and magne-
sium-free Dulbecco's phosphate-buffered solution
(DPBS, Invitrogen) and dissociated with 0.25% trypsin/
EDTA solution (Invitrogen). The suspension was centri-
fuged and the cell pellet was ressuspended in DMEM (Inv-
itrogen) with 10% FBS (Invitrogen) containing the
fluorescent dye (Vybrant CM-Dil Cell-Labelling Solution;
Molecular Probes, Invitrogen). Cells were incubated for
15 minutes at 37°C, washed twice in DPBS immediately
prior to intraperitoneal injection in mice.
Muscle biopsy and histology
Biceps femoralis biopsy samples were taken before the
hIDPSC transplantation experiment on day 0 (d 0) and
after 47, 107 and 117 days in different animals as summa-
rized in Table 1. A second biopsy was taken from the male
under systemic SC, delivery (MT1-S), after one year of
treatment. Each biopsy from biceps femuralis was divided
into 3 fragments for histological, immunofluorescence/
WB and FISH analyses. For IF analysis, tissue samples were
embedded in Jung Tissue Freezing Medium (Leica
Mycrosystems Nussloch GmbH, Nussilosh, Germany)
and frozen in liquid nitrogen. For WB analysis, 2 mm2
fragments were frozen directly in liquid nitrogen in small
flasks. For histological analysis routine hematoxylin and
eosin (HE) staining was applied.
Immunohistochemistry and Confocal microscopy
Differentiated cells were fixed in 4% paraformaldehyde
for 2 h at 4°C, washed three times in wash buffer (150
mM NaCl, 1 mg/ml BSA, 0.5% Nonidet P- 40, 50 mM Tris
pH 6.8) and membranes were permeabilized with two 10
min incubations in RIPA (150 mM NaCl, 1% Nonidet P-
40, 0.5% sodium deoxycolate, 0.1% SDS, 1 mM EDTA, 50
mM Tris pH 8.0). Cells were subsequently re-fixed in 4%
PFA for 30 min at 4°C, blocked in wash buffer for 1 h at
4°C and incubated overnight at 4°C with primary anti-
bodies. Cy3-conjugated goat anti-(mouse IgG) secondary
antibody and FITC-conjugated goat anti-(rabbit IgG) sec-
ondary antibody, normal mouse IgG and normal rabbit
IgG were used. The primary antibody was omitted from
some slides to serve as a negative control.
Myogenic differentiation was characterized using mouse
anti-human muscle α-actinin antibody and rabbit anti-
human muscle myosin antibody (Santa Cruz Biotechnol-
ogy, CA, USA) and by RT-PCR using MyoD1(MD1) for-
ward primer 5'AAGCGCCATCTCTTGAGGTA3' and
reverse primer 3'GCCTTTATTTTGATCACC5' following
the protocol described previously[13].
Tissues samples were excised, immediately frozen in liq-
uid nitrogen and then stored at -80°C. Cryostat tissue sec-
tions with 5 μm thickness were mounted on a glass slide.
According to the antibody used, slides were fixed and
dehydrated with cold methanol (Merck, Darmstadt, Ger-
many). To detect the presence of hIDPSC mouse, anti-
hIDPSC antibody previously obtained [13] was used at a
1:500 dilution, whereas mouse anti-human nuclei anti-
body (Monoclonal, Chemicon International, California,
USA) was used at a 1:100 dilution followed by FITC-con-
jugated secondary antibodies of respective isotype at a
1:1000. Dystrophin analysis was done using IF by apply-
ing the methodologies from our group [19]. Human spe-
cific anti-dystrophin monoclonal Mandys106 2C6
antibody was kindly provided by Dr. Glenn E. Morris at
Center for Inherited Neuromuscular Diseases, Oswestry,
UK [20]. Antibody DYS2 (Vector Laboratories – Burlin-
game, CA) against the C-terminal domain of dystrophin
and anti-mouse IgG Cy3- conjugated secondary antibody
were also used to confirm the presence of some positive
dystrophin fibers. Microscope slides were mounted in
Vectashield mounting medium (Vector Laboratories) with
or without 4',6-Diamidino-2-phenylindol (DAPI). IF
analysis was done in a Zeiss Imager Z1 Apotome micro-
scope with epi-fluorescence, or using an argon ion laser
scan microscope LSM 410 (Zeiss – Jena, Germany).
Confocal microscopy: An argon ion laser set at 488 nm for
FITC and at 536 for rodamine excitation were used. The
emitted light was filtered with a 505 nm (FITC) and 617
nm (rodamine) long pass filter in a laser scan microscope
(LSM 410, Zeiss – Jena, Germany). Sections (5 mm) were
taken approximately at the mid – height level of tissues.
Photo-multiplier gain and laser power were kept constant
throughout each experiment.
Fluorescent in situ hybridization (FISH)
FISH analysis was done with specific centromere probes
for human chromosomes X (green) and Y (red) (Aqui-
arius-Cytocell, Cambridge, UK). Tissue samples were fixed
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in 4% paraformaldehyde, embedded in Jung Tissue Freez-
ing Medium and 5 μm sections were made.
The slides with sections were then fixed with cold metha-
nol (Merck, Darmstadt, Germany) and dehydrated in
series of ethanol. FISH reactions were done according to
the manufacturer's protocol. Microscope slides were
mounted in antifade (Vectashield mounting medium)
with or without Propidium Iodide (PI, Vectashield
mounting medium/PI). FISH analysis was made using
confocal microscope as described above.
Biochemical analysis
Dogs underwent periodic veterinary examinations during
treatment. Blood samples were collected monthly by jug-
ular venipuncture. Hematological and serum biochemical
testing were performed with an automated cell counter
(Baker System 9000, Serno-Baker Diagnostics Inc, Allen-
town, Pennsylvania). Urea, alanine aminotransferase
(ALT), alkaline phosphatase (ALP), creatine kinase (CK)
and creatinine were measured in serum with an auto-
mated analyzer (Labtest® – LABTEST Diagnóstica S.A. –
Lagoa Santa, MG). Data are shown in Table 2.
Table 2: Serum biochemical analyses in four GRMD dogs under hIDPSC therapy (MT1, MT2, FT1 and FT2) and matched age control 
(MC and FC).
ANIMALS 30 
days
CK (U/L) ALT (U/L) FA (U/L) Urea 
(mg/dL)
Creat 
(mg/dL)
RBC (mlh/
mm3)
Ht (%) Hb (g/dL) WBC (mil/
mm3)
Reference values* 0–200 until 50 until 130 until 40 until 1.5 – 2 3.5 – 6 26 – 39 8.5 – 13 8,5 – 17,3
FC 9,275 162 500 31 1 3.3 27 7.1 19,300
FT1-S 9,274 159 478 28.6 1 3.6 25 7.6 26,300
FT2-IM 4,647 134 352 22 0.98 4 26 8.8 32,000
MC 3,618 110 260 32.8 1 4.2 30 8.8 32,300
MT1-S 7,716 230 174 30 1 4.6 34 11 24,800
MT2- IM 5,668 163 217 32.9 1.1 4.7 33 11.5 23,600
ANIMALS 75 
days
CK (U/L) ALT (U/L) FA (U/L) Urea 
(mg/dL)
Creat 
(mg/dL)
RBC (mlh/
mm3)
Ht (%) Hb (g/dL) WBC (mil/
mm3)
FC 32,599 294 300 46 0.85 4.8 29 9.2 28,200
FT1-S 15,100 245 161 43.5 0.92 4.3 26 8.7 34,800
FT2-IM 24,784 192 117 37.8 0.9 4.6 28 9.2 30,200
MC 15,257 189 138 37.8 0.9 4.1 27 8.9 36,600
MT1-S 30,729 293 181 42.8 0.94 4.6 29 9.9 25,900
MT2- IM 15,291 237 191 46.9 0.92 4.6 28 9.7 39,100
ANIMALS 180 
days
CK (U/L) ALT (U/L) FA (U/L) Urea 
(mg/dL)
Creat 
(mg/dL)
RBC (mlh/
mm3)
Ht (%) Hb (g/dL) WBC (mil/
mm3)
Reference values* 0–200 until 50 until 130 until 40 until 1.5 – 2 5.5 – 7 34 – 40 11 – 15.5 8 – 16,000
FC 56,736 416 58 40 0.4 5.5 39 12.4 16,200
FT1-S 48,960 396 28 23 0.5 5.4 38 12.1 15,500
FT2-IM 51,296 228 8 38 0.4 6.0 39 13.1 14,100
MC 56,736 524 91 51 0.5 5.6 37 12 20,400
MT1-S 25,632 440 66 55 0.4 5.5 36 12.5 18,600
MT2- IM 36,512 500 62 40 0.4 5.5 38 12 15,600
ANIMALS 360 
days
CK (U/L) ALT (U/L) FA (U/L) Urea 
(mg/dL)
Creat 
(mg/dL)
RBC (mlh/
mm3)
Ht (%) Hb (g/dL) WBC (mil/
mm3)
reference 
values*
0–200 until 50 until 130 until 40 until 1.5 – 2 5 – 8 37 – 54 12 – 18 6 – 15,000
FC**
FT1-S **
FT2-IM 35,712 764 8 35 0.4 6.1 41 13.1 14,000
MC 41,920 376 49 48 0.6 5.6 36 13 20,000
MT1-S 40,384 604 41 34 0.5 5.2 33 12 18,000
MT2- IM*** 9,280 208 33 50 0.7 5.1 34 11.7 15,000
GRMD 
Control Data 
(n:6)
35,710 551 43.25 35.75 0.52 5.75 37.75 12.87 14,6
Normal Dogs 
Data (n: 6)
145 15 82 28 1.8 4.2 30.7 14.2 11,7
Also, control dogs were used from all colony animals (Normal X Affected)
*Reference values from Veterinary Hospital (HOVET) – FMVZ-USP and FMVZ-UNESP, São Paulo, Brazil.
** Animal died with 10 months (FC) and 8 months (FT1-S) *** Animal died with 13 months
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Physical score exams
We established a physical exam score (Table 3), adapted
from literature [21] that evaluated dogs motility and pos-
ture, and which gave values between 0 (normal) to 24
(severely affected).
Results
Evaluation of hIDPSC skeletal myogenic potential and 
migrating ability
Isolated hIDPSC (2n = 46, XY) were used at passages 6 or
7 [13]. Because cells have been cryopreserved, we checked
their morphology (Figure 1A), proliferation efficiency
(Figure 1B) and expression of principal MSC markers such
as SH2, SH3 and SH4 (Figure 1C–F), prior to their use.
Additionally, cells were re-analyzed prior to transplanta-
tion. Their in vitro ability to differentiate into myotubes
was confirmed by immunostaining of α-actinin (sarcom-
eric) (Figure 1G) and of myosin (Figure 1H) and by RT-
PCR of the MyoD1 gene (Figure 1I). After thawing, migra-
tion ability of CM-DiI-fluorescently labeled hIDPSC (105)
was confirmed by its detection in the heart muscle of
intraperitoneal injected normal mice after 2 weeks (Figure
1J–M). No prior immunosuppression was done.
hIDPSC transplantation in GRMD dogs
To minimize the effects of inter and interfamilial variabil-
ity previously observed in GRMD dogs we used animals
from the same litter. Six affected animals (3 males and 3
females) born after the breading of an affected male with
a carrier female through artificial insemination were used
in the experiment. The dystrophin mutation in these pup-
pies was confirmed by PCR (Figure 2). Cells were injected
in four dogs, two MT1-S (male transplanted 1- systemic)
and MT2-IM (male transplanted 2- intramuscular) and
two females FT1-S (female transplanted 1-systemic) and
FT2-IM (female transplanted 2- intramuscular). Each gen-
der received 6 × 107 hIDPSC via arterial or muscular injec-
tion. One non-injected male (MC – male control) and one
non-injected female (FC – female control) were analyzed
as age-matched controls (Table 1). The first systemic and
local injections were done respectively in two 28- days-old
female dogs. To verify the potential effect of short- and
long-term treatment with hIDPSC, females received one
unique injection, whereas males were treated with
monthly injections, starting with 44 days old.
Table 3: Physical exams score for motility and postural features from dystrophic dogs
Scores
CRITERIA 0 1 2
1. Posture symmetry Symmetric animal Slight asymmetry: discreet lordosis High asymmetry: lordosis posture 
and tail elevation
2. Increase of tarsal normal angle 
(plantigrady)
Absent modest severe (walk on tarsus)
3. Increase of carpal normal 
angle (palmigrady)
Absent modest severe (walk on carpus)
4. Stifle stiffness while moving normal stifle motility slight stifle stiffness severe stifle stiffness associated with 
short strides
5. Pelvic balance
Normal reduced absent
6. Postural tone 
(muscle palpation and 
inspection)
normal tone hypotonic flaccid
7. Contractures Absent decrease in passive range of motion contractures limiting passive range 
of motion
8. Hopping
Normal reduced inability to achieve postural reaction
9. Standing up Normal ability reduced 
(perform task slowly/slower)
inability to stand up alone
10. Barrier crossing normal reduced inability to jump
11. Food prehension Eat normal dry food changed for wet food laborious swallowing
12. Locomotion apparatus 
structure
strong losing structures components as 
muscle mass and bone fragilities
weak and thin
Total score = 24
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Characterization, myogenic differentiation in vitro and migrating capacity in vivo of hIDPSCFigure 1
Characterization, myogenic differentiation in vitro and migrating capacity in vivo of hIDPSC. (A) Fibroblast-like 
morphology of hIDPSC. (B) Proliferating potential of these cells during 16 successive passages. (C-E) Flow cytometry showing 
expression of CD105 (SH2), CD73 (SH3 and SH4), respectively. (F) Negative control for respective isotype. (G,H) Myogenic 
differentiation in vitro: fused hIDPSC forming myotubes. Positive immunostaining with α-actinin (G) and myosin (H): insets in (G 
and H) show details of anti-bodies localization within myotubes, higher magnification. (I) RT-PCR analysis of the expression of 
human dystrophin (MyoD1) observed hIDPSC and human muscles, used as a positive control. (J-M). Migrating capacity of 
hIDPSC visualized 30 days after their intraperitoneal injection into normal mice (J-M): (J) Cells stained with DiI-Vybrant (red) in 
mouse, (K) positive reaction with primary human anti-IDPSC antibody in mice (secondary antibody FITC-conjugated was used 
(green), (L) Morphology of mouse cardiac muscles. (M) merged image of J-L. A= light microscopy, phase contrast, G-H = epi-
fluorescence (EF), J-M= confocal microscopy: J, K = fluorescent microscopy (Fcm), L = DIC (Differential interference contrast) 
M = Fcm+DIC. Scale bars: G,H = 10 μm, A,J-M = 100 μm, N-P = 50 μm
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One male (MT2-IM) received six intramuscular (biceps
femularis) injections, whereas another subject (MT1-S)
received nine arterial (femoral artery) systemic injections.
No immunosuppression was used before or after cell
transplantation. Muscle biopsies were obtained at the
beginning of the experiment (d 0) from FC only; after 107
days in the three females and after 47 and 117 days only
from the injected male dogs. After one year, a muscle
biopsy was collected from MT1-S.
Engraftment of hIDPSC in muscles of GRMD dogs after 
transplantation
Serial frozen sections of canine muscles were analyzed for
engraftment. Scattered human cells were identified in
females who received one injection of hIDPSC each. Only
some of the sections obtained from these animals showed
a few human anti-hIDPSC antibody positive fibers along
with the presence of human cells in muscles and connec-
tive tissues, and probably in the region of injection from
dog FT2-IM, representative by Figure 3A. MT1-S presented
an apparently higher engraftment of hIDPSC in muscle
fibers, as demonstrated by anti-hIDPSC antibody, which
were detected in several sections of the biopsies (Figure
3B–J). Transversal sections (serial-section analysis) from
canine/human chimeric muscle fibers showed variable
engraftment within different fibers as well as within one
fiber, which indicates the occurrence of fusion between
both cell types (Figure 3B–D,I,J). FISH analysis with
human Y and X DNA probes confirmed these results and
showed their presence in chimeric muscle fibers. Interest-
ingly, FISH experiments showed human nuclei in the cen-
tral part of the fibers; in a pattern resembling those of
immature myotubes (Figure 3K and inset). Further analy-
sis using FITC-conjugated anti-human nuclei specific anti-
body also showed the presence of human nuclei in several
MT1-S muscle fibers (Figure 3L–P).
Human dystrophin expression in muscles of GRDM dogs
After 107 and 117 days, immunofluorescence (IF) analy-
sis of muscle biopsies from the four injected dogs detected
few fibers labeled with human specific anti-dystrophin
antibody (Mandys1062C6), (data not shown). However,
scattered large fibers positive for this antibody were
observed after one year of consecutive injections in MT1-
S (Figure 4A–D). The expression of dystrophin in this ani-
mal was also confirmed with a C-terminal antibody for
dystrophin (Figure 4E–J). However, the expected band of
427 kDa was not observed in western blot (WB), which
may indicate that only a small amount of the expressed
protein was present in the sample (data not shown).
Histological characterization of GRMD dogs after 
treatment with hIDPSC
Muscle degeneration showing necrosis, splitting, centrally
located nuclei, and significant endomysial and perimysial
connective tissue replacement was observed in all injected
and not injected muscles. Interestingly, muscle his-
topathological analysis of MT1-S done one year after the
first injection showed a high number of very large fibers,
with several centrally located nuclei associated to a signif-
icant proportion of splitting fibers which is suggestive of
segmental necrosis (Figure 4K,L). FISH and anti-human
nuclei specific antibodies results supported that hIDPSC
can contribute for the formation of these large centrally
nucleated fibers (Figure 3K,M–O).
Clinical and laboratorial assessment
Several biochemical parameters were assessed in all dogs
monthly and analyzed at times 30, 75, 180, 360 days
(Table 2). Mean serum CK showed a peak between 75 to
180 days with an apparent stabilization afterwards. Other
biochemical parameters summarized in Table 2 suggest
that all treated dogs maintained liver and kidney func-
tions and apparently did not show any evident alteration
in response to cells transplantation such as white blood
cell counting (WBC).
The progression of the dystrophic process was analyzed
based on a mobility score which is summarized in Table
1. One affected female control (FC) and two dogs under
treatment died during the experiment (FT1-S and MT2-
IM). The motility score showed a moderate disease pro-
gression in dogs MT1-S and FT2-IM. Although when com-
paring male and female phenotypes, it should be taken
into consideration that females locomotion apparatus dif-
fers from males since they have a lighter bone structure, a
smaller body and a more delicate locomotion pattern.
MT1-S, at one year old, showed a good performance with
DMD genotypingFigure 2
DMD genotyping. GRMD puppies from a colony of dogs 
with X-linked muscular dystrophy were genotyped within 48 
hs after birth. The genomic PCR product digested with 
Sau96I produces the wild type band (310 pb) and the mutant 
band (150 pb) labelled with arrows. ■ = Affected male. ● = 
Affected female.< = Carrier female.
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Representative figures of hIDPSC engraftment observed within canine skeletal muscles (GRMD)Figure 3
Representative figures of hIDPSC engraftment observed within canine skeletal muscles (GRMD). (A) FT2-IM, 
after 107 days of single transplantation: Positive immunostaining with anti-hIDPSC antibody (green) was observed in several 
muscle fibers (white arrowhead) and in the nuclei (white arrows, blue, DAPI stained superposition with anti-IDPSC antibody, 
green) of hIDPSC localized in the periphery of canine muscle fibers. (B-I) One year after multiple hIDPSC transplantation. Pos-
itive immunostaining with anti-IDPSC antibody was observed in MT1-S muscles: (B-D) transversal and (E-H) longitudinal sec-
tions. Inset in (F) demonstrate (higher magnification) skeletal muscle Z-bands (red arrowhead) observed in the local of positive 
immunostaining with anti-hIDPSC antibody (DIC). (H) Higher magnification of (G) demonstrating positive reaction of hIDPSC 
antibody (green) with skeletal muscle Z-bands (red arrowhead). (I) Chimeric human/canine muscle fiber only a half of which 
presents positive green fluorescent immunostaining (green). (J) Control: affected male without hIDPSC transplantation immu-
nostained with anti-hIDPSC antibody did not present any labeling. (K) FISH analysis of dystrophic male's muscles using specific 
human probe for chromosome: Y (red) and in inset X (yellow, as a result of merged images of PI (red) stained nucleus and 
probe of chromosome X (green) are presented). (L-P) Immunostaining using FITC conjugated anti-human nucleus (anti-HN) 
antibody (green). (L) Positive control. Merged image of positive staining with anti-HN antibody and nuclei stained with DAPI in 
normal human muscles. (M-O) Positive immunostaining with anti-HN antibody observed in the nuclei of hIDPSC (green) 
engrafted into canine muscle fibers of MT1-S. They (white arrowhead) can be seen within canine muscle fibers and in perimy-
sium (white arrows). Canine nuclei (group of 4 nuclei indicated by red arrow) did not present any reaction with anti-HN anti-
body. (P) Negative control. Muscles of normal dog did not react with anti-HN antibody. Only nuclei stained with DAPI can be 
observed. Confocal microscopy, A,D,G-L,P = Fcm+DIC; C,F,M,N = Fcm, B,E, Inset in (F) = DIC, Scale bars: A-H, L,P = 50 μm, 
K = 100 μm, and M-O = 20 μm, Inset in (K) = 10 μm
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moderate scores mainly in postural tone, standing up,
crossing barriers and hoping. Currently, at age of 18
(Additional file 1) and 25 months (Additional files 2 and
3) his motility is stable and he is doing well. In our expe-
rience almost 90% of the GRMD dogs die before 24
months of age. However, Chokito, the dog in which we
found a greater amount of muscle dystrophin is showing
a better course. The movies show this dog at 18 and 26
months old and so far he showed no decline.
FT2-IM had a comparable performance but she died sud-
denly of cardiac arrest at age of 16 months (Table 1, 2, 3).
Discussion
Herein we showed that hIDPSC were capable to migrate
and engraft into GRDM dog muscle as confirmed by FISH
and immunohystochemical analyses. Due to our ethical
committee rules which is against dogs euthanasia or tak-
ing multiple biopsies we did not quantify the engraftment
of these cells into different muscles, however all analyzed
biopsy fragments demonstrated the presence of hIDPSC.
We observed that these cells were able to form chimeric
canine/human fibers with recipient muscles, although the
expression of human dystrophin was observed only in
limited number of the fibers following early, multiple cell
transplantation. Additionally, these cells persisted in the
host muscle for at least 1 year. Moreover, it has been sug-
gested that thawing might modify the properties of SC
[22].
Two independent groups have previously reported the
transplantation of different types of canine stem cells in
Immunofluorescence analysis using the specific human anti-dystrophin monoclonal antibodies: Mandys106 2C6 (A-D) and C-ter i al (E-J) antibodies one year after th  hIDPSC transplantati nFigure 4
Immunofluorescence analysis using the specific human anti-dystrophin monoclonal antibodies: Mandys106 2C6 
(A-D) and C-terminal (E-J) antibodies one year after the hIDPSC transplantation. (A) Positive control: expression 
of Mandys106 2C6 antibody in normal human muscles. (B) Negative control: lack of expression of same antibody in the mus-
cles of normal dog. (C, D) MT1-S shows positive staining with Mandys106 2C6 in large dystrophic fibers (white arrows). (E) 
Positive control: expression of C-terminal in normal human muscles. (F) C-terminal antibody in the muscles of normal dog 
presents weak labeling. (G) Negative control: lack of its expression in the muscles of affected dog. (H-J) MT1-S shows positive 
staining with C-terminal antibody in some large dystrophic fibers (arrow). K) Toluidine blue and L) HE staining shows very 
large fibers with multiple centrally located nuclei and splitting. A, C, E-H = Fcm + DIC, B = DIC, D,I,= EF, J,K = Light micros-
copy, Scale bars = 50 μm
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the GRMD model. In the first study, 7 dogs received
canine allogenic hematopoietic cell transplantation at
ages 4.5 to 5.5 months [10]. However, donor cells did not
show any significant contribution to the injured skeletal
muscle nor significant increase of dystrophin positive fib-
ers, although near-complete or complete donor hemat-
opoietic chimerism was detected in physically active dogs.
The authors concluded that allogenic bone marrow cell
transplantation is not a viable therapy in its current form
due to the absence of clear clinical benefits [10]. The sec-
ond group used canine heterologous wild type (WT) mes-
oangioblasts and allogenic genetically modified
mesoangioblasts [11]. The authors reported GRMD mus-
cle function improvement and high level of dystrophin
expression in particular after heterologous wild-type (WT)
mesoangioblasts transfer, but less with autologous genet-
ically modified SC. Both early and late SC transplantation
showed very promising results [11]. However, since
immunosuppression was applied in both studies; clinical
interpretation of the results is difficult because the use of
anti-inflammatory molecules may improve muscle func-
tion in affected muscular dystrophy patients [12].
The number of animals, which received SC transplanta-
tion in present work, was just the same used in previous
publications [10,11]. However, our study differs in several
aspects. First, we used in our experiments an exceptional
litter with 3 affected females and 3 affected males. Second
we transplanted human, not canine SC without the inter-
ference of immunosuppression protocols. Third, clinical
monitoring of dogs showed no signs of fever, skin erup-
tion, arthralgia or even glottis edema suggesting, that
human cells were well accepted by the dog organism.
As canine mesoangioblasts and hIDPSC are derived from
different tissues and species, it is difficult to compare their
potential benefits after transplantation in the GRMD
model. However, both cell types proliferate efficiently and
present a good migrating capacity in host tissues [10,11].
In our experiment, in contrast to the study reported by
Cossu group [11] we did not observe significant increase
of dystrophin positive fibers in the 4 GRDM dogs after SC
transplantation. Although all dogs showed engraftment of
hIDPSC in muscles, only one of them (MT1-S) showed
human dystrophin expression. However, this dog, which
received the largest amount of human stem cells, is still
alive and well at 25 months of age after the experiment
was over. It showed a slower rate of progression of the dys-
trophic process than his five litter-mate dogs or to most of
the dogs from the Brazilian GRMD colony, since the
majority of them died before 18 months of age (unpub-
lished observation).
At the end of the experiment, MT1-S had no difficulties in
swallowing or chewing hard food, maintained jaw
strength as well as the ability to run while carrying objects.
The female FT2-IM had also good clinical scores despite
the fact we could not detect dystrophin in her muscle
biopsy. It died suddenly of cardiac failure at 16 months of
age. Due to females having a more delicate structure of the
locomotion apparatus and other anatomical variation in
the thorax and muscle structures [23], gender could
indeed have interfered with muscle functions and motility
performance. Furthermore, since female GRMD dogs are
very rare, there are no parameters to evaluate the natural
history of their disease, not to mention the absence of
studies that use such dogs. FC, FT1-S, FT2-IM and MT2-IM
died from dystrophy complications at the ages 10, 8, 16
and 11 months, respectively.
In DMD patients, serum CK is elevated since birth and
shows a peak of activity around 2 to 4 years when there is
massive muscle degeneration [24]. In accordance with
Sampaolesi studies [12] we observed that mean serum CK
activities in GRMD dogs were higher between 75 to 180
days followed by an apparent stabilization (Table 2).
Significant immune modulatory function of MSC has
been demonstrated in hematopoietic stem cell transplan-
tation. They strongly inhibit alloantigen-induced den-
dritic cell differentiation, down-regulate alloantigen-
induced lymphocyte expansion, decrease alloantigen-spe-
cific cytotoxic capacity mediated by either cytotoxic T lym-
phocytes or NK cells. Interestingly, a more effective
suppressive activity on mixed lymphocyte culture-
induced T-cell activation was observed when MSC were
heterologous rather than autologous. It was suggested that
due to these properties, MSC can be used to prevent
immune complications related to both hematopoietic
stem cells and solid organ transplantation and it was pro-
posed that MSC are "universal" suppressors of immune
reactivity. Moreover, it was shown that regulatory CD4+
or CD8+ lymphocytes were generated in co-cultures of
peripheral blood mononuclear cells with MSC. This
strongly indicates that these regulatory cells may amplify
the reported MSC-mediated immunosuppressive effect
[25-27]. In our experiments the dogs did not show any
immune reaction to hIDPSC transplantation. This could
be explained by the fact that according to previous publi-
cation immunosuppressive activity of human DPSC was
significantly higher, when compared to those from bone
marrow [15]. More recently, similar results were observed
with different populations of stem cells isolated from den-
tal pulp [14,15,17].
The absence of dogs immune response to hIDPSC trans-
plantation here reported for the first time is an important
observation, because anti-inflammatory drugs could
occult the benefits of stem cells therapy for dystrophy
[28]. Indeed, white blood cells counting did not present
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any important changes in response to cell transplantation
and no lymphocytes infiltration was observed in muscle
cells. We also did not observe immune reactions using the
same cells in experiment on reconstruction of cranial
defects in rats [14]. This result is also supported by other
authors, which demonstrated that human stem cell iso-
lated from dental pulp have immunosuppressive activity
[15]. In conclusion, we believe that rejection of hIDPSC
did not occur since they present all basic characteristic of
mesenchymal stem cells [29].
It is very tempting to suggest that the presence of some
dystrophin in muscle as a result of repeated systemic
hIDPSC transplantation ameliorated the clinical condi-
tion of MT1-S since this disease in dogs causes their death
usually between 11 and 18 months [9,30]. Interestingly,
after transplantation of human DPSC in non immuno-
suppressed rats with acute myocardial infarction, surviv-
ing and engraftment of the cells in ischemic environments
have been observed. Although no differentiation into car-
diac or smooth muscle as well as into endothelial cells
was observed, these cells apparently contributed for the
improvement of left ventricular function, induced angio-
genesis and reduced infarct size. According to the authors,
the benefits observed after DPSC transplantation might be
due to secretion of paracrine factors by these cells [17].
Since the expression of dystrophin was modest, clinical
improvement in this dog might be the result of the
immune modulatory effect of hIDPSC transplantation
rather than the presence of dystrophin, or rather than the
great clinical variability observed among GRMD dogs
[31]. However, our preliminary results, which should be
validated in a larger sample, suggested that multiple sys-
temic transplantations of hIDPSC in GRMD dogs could
slow down the progression of the dystrophic process,
through similar mechanisms described by Gandia and co-
workers [17].
In short, our investigation confirmed that early systemic
delivery of SC in GRMD model is more effective than local
injections. Although we showed that donor human SC
can engraft, differentiate, and persist in the host, it seems
that the apparent clinical benefit observed in treated ani-
mals is not due to dystrophin expression in the host mus-
cles, but due to their immune modulatory effect of SC
from dental pulp [14,15,17,32]. However, both observa-
tions that cell engraftment increases with consecutive
transplantation and the absence of immunological
response, have very important implications in designing
future therapeutic trials. The potential clinical effect of SC
in GRMD model should be supported by further investi-
gation involving a larger number of animals and the effi-
cacy of later as compared to early transplantation.
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